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Recent studies identiﬁed a highly tumorigenic subpopulation of glioma stem cells (GSCs) within malignant gliomas. GSCs
are proposed to originate from transformed neural stem cells (NSCs). Several pathways active in NSCs, including the Notch
pathway, were shown to promote proliferation and tumorigenesis in GSCs. Notch2 is highly expressed in glioblastoma
multiforme (GBM), a highly malignant astrocytoma. It is therefore conceivable that increased Notch2 signaling in NSCs
contributestotheformationofGBM.Here,wedemonstratethatmiceconstitutivelyexpressingtheactivated intracellulardomain
ofNotch2inNSCsdisplayahyperplasiaoftheneurogenicnicheandreducedneuronallineageentry.Neurospheresderivedfrom
these mice show increased proliferation, survival and resistance to apoptosis. Moreover, they preferentially differentiate into
astrocytes, which are the characteristic cellular population of astrocytoma. Likewise, we show that Notch2 signaling increases
proliferation and resistance to apoptosis in human GBM cell lines. Gene expression proﬁling of GBM patient tumor samples
reveals a positive correlation of Notch2 transcripts with gene transcripts controlling anti-apoptotic processes, stemness and
astrocytefate,andanegativecorrelationwithgenetranscriptscontrollingproapoptoticprocessesandoligodendrocytefate.Our
data show that Notch2 signaling in NSCs produces features of GSCs and induces astrocytic lineage entry, consistent with a
possible role in astrocytoma formation.
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Gliomas are the largest group of primary tumors in the brain
and include morphologically distinct astrocytomas and oligo-
dendrogliomas. Glioblastoma multiforme (GBM), the most
aggressive form of malignant astrocytomas, offers limited
therapeuticoptions with a median survivalforGBM patientsof
less than 14 months.
1 Malignant gliomas contain a highly
tumorigenic population of glioma stem cells (GSCs) that are
deﬁnedbytheirabilitytoself-renew,togiverisetoallcelltypes
within a particular glioma and their resistance to apoptosis.
2–7
Due to their longevity, self-renewal and sustained proliferative
capacity, neural stem cells (NSCs) are a likely source for
GSCs.
2–7 In addition, the pluripotency of NSCs provides a
rationale for the cellular heterogeneity observed in gliomas.
1
Dysregulation of genes controlling cell cycle, differentiation
and apoptosis in NSCs may therefore promote their transfor-
mation into GSCs.
2–7 Intriguingly, Notch2 was shown to be
highly expressed in GBM, and the Notch2 gene was found
to be ampliﬁed in many primary GBM cell lines.
8 Moreover,
elevated Notch2 signaling increased GBM growth and reduced
survival in mouse xenograft models.
9 In contrast, Notch2
deletions are frequently observed in oligodendrogliomas and
are associated with a more favorable prognosis.
10 Together
these data support that Notch2 is a prognostic marker and
possiblyinvolvedinmalignantprogression.However,whether
aberrant Notch2 signaling contributes to NSC transformation
and ultimately to gliomagenesis is not known.
Four Notch receptors (Notch1–4) exist in mammals.
11
Binding of ligands triggers a proteolytic processing of
receptors and translocation of Notch intracellular domains
(NICDs) to the nucleus. NICD binding to a transcriptional
complex, including RBPjk and MAML1, leads to transcrip-
tional activation of the effector genes Hairy and Enhancer of
Split homologs (e.g., Hes1 or Hes5).
11,12 Notch2 regulates
morphogenesis of Bergmann glia cells
13 and inhibits granule
neuron differentiation in the cerebellum.
14 Moreover, Notch2
is expressed throughout the embryonic
15,16 and adult neuro-
genic regions.
16,17 However, although Notch1 signaling was
showntoregulateproliferation, cellfatedecisionsandsurvival
in NSCs,
12,18–21 a role for Notch2 in NSC regulation is not
established.
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www.nature.com/cddisHere, we report that constitutive expression of the intra-
cellulardomainofNotch2(N2ICD) inNSCsintransgenic mice
promotes proliferation and prevents neuronal lineage entry.
NSCsfromthesemiceexhibitincreasedproliferation,reduced
apoptosis and preferentially differentiate into the astrocytic
lineage. Likewise, modulation of Notch2 signaling regulates
proliferationandapoptosisinhumanGBMcelllines.Thus,our
data support that aberrant Notch2 signaling contributes to
NSC transformation and possibly to GBM formation.
Results
N2ICD expression in embryos causes severe hyperplasia
and inhibits neurogenesis. To study the role of Notch2
signaling in the developing brain, we crossed Nestin-Cre
mice
22 with N2ICD mice
23 to drive expression of myc-tagged
N2ICD in NSCs and their progeny (Nestin-Cre/N2ICD mice;
Figure 1a). Western blot analysis revealed expression of
myc-tagged N2ICD in the brain of E18.5 Nestin-Cre/N2ICD
mice (Figure 1b). In addition to the expected increase in
Notch2 mRNA due to N2ICD transgene expression, Nestin-
Cre/N2ICD mice also showed increased mRNA levels
for its target genes Hes1 and Hey1 when compared with
control mice (Figure 1c). This demonstrates that the trans-
gene generates functional N2ICD. E18.5 Nestin-Cre/N2ICD
embryos displayed enlarged ventricles and a hyperplasia of
the ganglionic eminence, the neurogenic region in the ventral
forebrain (Figure 2a). The ganglionic eminence displayed a
threefold increase in size (Figure 2b) and an enlarged region
of NSCs identiﬁed by Ki67 (Figure 2c) and Nestin immuno-
staining (Supplementary Figure 1A). The striatal region
of E18.5 Nestin-Cre/N2ICD embryos had an increased
cell density and lacked the striasome, a typical porous
structure (Figure 2d). Moreover, the striatal region lacked
immunostaining for Substance-P and GAD65/67, which are
commonly used to outline the striatum in the ventral forebrain
(Figure 2d). NeuN immunostaining showed that the ventral
forebrain of Nestin-Cre/N2ICD mice is not only devoid
of GAD65/67þ interneurons but also mature neurons in
general (Supplementary Figure 1B). It therefore appears
that the striatal region is mainly populated by an increased
number of Nestinþ NSCs failing to develop into neurons.
Strikingly, the consequences of constitutive N2ICD expres-
sion in NSCs are detrimental, as Nestin-Cre/N2ICD mice die
at birth. In summary, the above experiments support a dual
role for Notch2 during embryogenesis, both in increasing
proliferation and inhibiting neurogenesis.
N2ICD expression in adult mice increases proliferation
and inhibits neuronal differentiation in neurogenic niches.
GBM mostly occur in adults and therefore N2ICD expression
in adult NSCs more accurately addresses a possible role of
Notch2 in gliomagenesis. The perinatal lethality of Nestin-
Cre/N2ICD mice precludes studying a possible role of Notch2
in malignant transformation of adult NSCs. We therefore
crossed N2ICD mice with double transgenic GFAPCreER
T2/
R26R-YFP (GCE/YFP (yellow ﬂuorescent protein)) mice to
generate triple transgenic GCE/YFP/N2ICD mice.
24,25 These
mice allow for tamoxifen-induced N2ICD and YFP expression in
adult GFAPþ NSCs and astrocytes
24 (Figure 3a). GCE/YFP
mice, which express YFP but not N2ICD upon tamoxifen
induction, were used as littermate controls. GCE/YFP/N2ICD
mice exhibit a twofold increase in Ki67þ proliferating YFPþ
cells in the subventricular zone and the subgranular zone
(SGZ) of the dentate gyrus, two prominent areas of neuro-
genesis in the adult brain (Figure 3b). This indicates that
N2ICD expression increases proliferation in NSCs in the
adult, similar as it does during embryogenesis.
We next analyzed whether N2ICD prevents neuronal
differentiation in the adult brain (Figure 3c). Brain sections
from GCE/YFP/N2ICD and GCE/YFP mice were co-immuno-
stained for YFP and markers for adult NSCs (Sox2, GFAP; of
note GFAP, which is widely used as a marker for astrocytes,
also labels NSCs in the dentate gyrus) or neuronal markers
(Dcx, NeuN). The dentate gyrus of GCE/YFP/N2ICD mice
showed approximately a twofold increase in YFPþ cells
expressing GFAP/Sox2 (Figures 3c, d). In addition, GCE/
YFP/N2ICD mice had a signiﬁcantly reduced number of
YFPþ cells expressing Dcx/NeuN (Figures 3c, d). This
shows that Notch2 signaling inhibits neuronal differentiation
of adult NSCs in the dentate gyrus.
N2ICD expression in neurospheres increases prolifera-
tion, promotes survival and astrocytic commitment.
To study NSC proliferation and expansion, we prepared
Figure 1 Transgenic expression of N2ICD in the neurogenic region. (a)
Breeding scheme for myc-tagged N2ICD expression in NSCs of Nestin-Cre/N2ICD
mice. (b) Western blot revealing myc-tagged N2ICD protein in the brains of E18.5
Nestin-Cre/N2ICD mice but not the brains of single transgenic N2ICD littermate
controlmice.Actincontrolsforsampleloading.(c)RT-PCRshowsincreasedmRNA
levels of Notch2 and its target genes Hes1 and Hey1 in the brains of Nestin-Cre/
N2ICD mice compared with control mice. Bar diagram shows mean±S.D.,
***Po0.001 (Student’s t-test)
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Cell Death and Diseaseneurospheres from the ganglionic eminence of E14.5 Nestin-
Cre/N2ICD and littermate control embryos (Figure 4a).
Neurospheres from Nestin-Cre/N2ICD NSCs were signiﬁ-
cantly larger than those from control NSCs (73.1±2.4mm,
n¼226 neurospheres versus 42.56±1.08mm, n¼224 neuro-
spheres, mean diameter±S.E.M., Po0.0001), indicating
that N2ICD expression increases NSC proliferation in
neurospheres (Figures 4a, b), similar as in vivo. Next, we
used neurospheres to study whether N2ICD regulates NSC
fate decisions. We differentiated neurospheres from E14.5
Nestin-Cre/N2ICD embryos in vitro and quantiﬁed cells
expressing the neuronal marker bIII-Tubulin (Tuj1), the
oligodendrocyte marker Olig2 and the astrocyte marker
GFAP (Figure 4c). A signiﬁcantly reduced number of Tuj1þ
cells in Nestin-Cre/N2ICD cultures indicates that N2ICD
prevents NSCs from efﬁciently differentiating into neurons
(Figures 4c, d). In contrast, differentiated Nestin-Cre/N2ICD
NSCs showed a signiﬁcant increase in GFAPþ astrocytes
(Figures 4c, e). Intriguingly, the staining intensity for GFAP in
differentiated Nestin-Cre/N2ICD NSCs was visibly increased
compared with the control (Figure 4c). Increased GFAP
protein levels and decreased Tuj1 protein levels were con-
ﬁrmed on immunoblots (Figure 4g). Moreover, the number
of Olig2þ oligodendrocytes was signiﬁcantly decreased in
Nestin-Cre/N2ICD NSCs (Figures 4c, f). This supports that
Notch2 signaling biases fate decisions in NSCs toward the
astrocytic lineage by inhibiting differentiation into neurons or
oligodendrocytes.
To test the role of N2ICD in NSC survival and apoptosis,
Nestin-Cre/N2ICD and control neurospheres were treated
with etoposide to induce apoptotic cell death. Etoposide is an
anti-cancer agent inhibiting topoisomerase II, which induces
DNA strand breaks. Etoposide is widely used in chemother-
apy, including the treatment of GBM.
26 In our experiments,
inductionofapoptosiswasmonitoredbyCaspase-3cleavage,
which is part of the apoptotic signaling cascade (Figure 4h).
Our results show that NSCs overexpressing N2ICD have
reduced levels of cleaved Caspase-3 compared with control
NSCs, supporting that Notch2 signaling prevents apoptosis.
N2ICD expression in human GBM cell lines increases
proliferation and prevents apoptosis. We studied
Figure 2 N2ICD expression in NSCs during embryogenesis results in a hyperplasia of the neurogenic region. (a) Cresyl violet stained coronal sections showing
hyperplasia of the neurogenic region (ganglionic eminence, GE; outlined by a dashed line) in E18.5 Nestin-Cre/N2ICD mice compared with control mice. E18.5 Nestin-Cre/
N2ICD mice also displayed enlarged ventricles (V) and a lack of a properly developed striatum (Str). (b) Quantiﬁcation of the ganglionic eminence revealed a more than
threefold increase in size in E18.5 Nestin-Cre/N2ICD mice compared with E18.5 controls. (c) Immunostaining for the proliferation marker Ki67 reveals a highly increased
population of proliferating cells in E18.5 Nestin-Cre/N2ICD mice compared with E18.5 control mice. (d) Immunostaining for the marker proteins GAD65/67 (arrowheads) and
SubstanceP(arrows)revealsthatNestin-Cre/N2ICDmicedonotexpresstheseproteinsintheventralforebrainofE18.5mice,incontrasttothestriatumofcontrolmice.DAPI
staining shows that the typical porous structure of the striasome (arrows in control mice) is lacking in E18.5 Nestin-Cre/N2ICD mice. Bar diagram shows mean±S.D.,
***Po0.001 (Student’s t-test). Scale bars are (a and c)¼200mm, (d)¼50mm
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Cell Death and Diseasewhether Notch2 signaling regulates proliferation and resis-
tance to apoptosis in GBM cells. To activate or inhibit Notch2
signaling in GBM cells, we stably transfected the human
GBM cell line U373 with N2ICD (U373-N2ICD cells) or
dominant-negative mastermind-like I (U373-MAML1dn cells),
which prevents canonical Notch signaling.
8,27 Transfected
GBM cells were cultured in neurosphere media under non-
adherent condition, which produced GSC-like spheres.
Compared with wild-type (WT) spheres, the size of N2ICD-
expressing spheres was signiﬁcantly increased, whereas
the size of MAML1dn-expressing spheres was signiﬁcantly
decreased (WT, 56±1.7mm, n¼90 spheres; N2ICD,
111±2.4mm, n¼215; MAML1dn, 41±0.5mm, n¼291;
mean diameter ±S.E.M., Po0.0001; Figures 5a and b).
The presence of GSC markers (Nestin, Sox2, and CD133) in
the spheres conﬁrmed that these derived from GSC-like cells
rather than from non stem-like GBM cells growing under non-
adherent conditions (Figure 5c).
To evaluate whether Notch2 signaling has a role in GBM
cells chemoresistance to cell death, U373-N2ICD and U373-
GFP (green ﬂuorescent protein) control GBM cells were
treated with etoposide. Both cell lines showed a higher
resistance to apoptosis induction compared with NSCs (data
not shown). In fact, etoposide treatment for U373 GBM cells
had to be prolonged to 24h to observe apoptosis. As with
N2ICD-expressing NSCs (Figure 4h), GBM cells expressing
N2ICD showed lower levels of cleaved Caspase-3 compared
with control GBM cells (Figure 6a). This result supports a role
for N2ICD activity in the chemoresistance of glioma cells to
apoptosis. In addition, U373-N2ICD GBM cells showed
increased levels of anti-apoptotic proteins such as Bcl-2 and
Mcl-1comparedwithcontrolGBMcells(Figure6a),inlinewith
the observed resistance to apoptosis. To further investigate
whether the prevention of apoptosis in U373 GBM cells is
mediated by canonical or non-canonical Notch signaling, we
treated U373-MAML1dn and U373-GFP control GBM cells
with etoposide. Caspase-3 cleavage in response to etoposide
was similar in the U373-MAML1dn and control U373-GFP
cells, showing that the inhibition of canonical Notch signaling
in U373-MAML1dn GBM cells does not increase apoptosis
(Figure 6b). Likewise, protein levels for Bcl2 and Mcl1 were
similar in U373-MAML1dn and U373-GFP control GBM cells
treated with etoposide (Figure 6b). It is therefore possible that
non-canonical Notch signaling prevents apoptosis, consistent
with previous reports.
28,29 Thus, Notch2 signaling not only
increases proliferation of GSC-like cells but also induces
chemoresistance of GBM cells to etoposide treatment, likely
by upregulating anti-apoptotic pathways.
Notch2 levels in primary human GBM correlate with
antiapoptotic, stem cell and glial markers. Analyzing
published microarray data,
30 we investigated whether Notch2
expression in primary human GBM samples correlates with
the expression of genes regulating cell differentiation and
survival (Figure 7 and Supplementary Table 1). Notch2
expression correlated with expression of the target genes
Hes1 and Hey1 (rs¼0.7 and 0.61). Transcripts for the anti-
apoptotic proteins BCL6 and BCL2L12 exhibited correlation
with Notch2 transcripts (rs¼0.75 and 0.67), whereas
transcripts for the proapoptotic proteins Bax and BCLAF1
Figure 3 Notch2 regulates proliferation and differentiation of adult NSCs. (a) N2ICD mice were mated with GFAPCreER
T2/Rosa26-YFP (GCE/YFP) mice, which yields
GCE/YFP/N2ICD mice that express both N2ICD and YFP upon tamoxifen-induced Stop codon excision in adult NSCs. YFP immunostaining in GCE/YFP/N2ICD mice was
therefore used to identify cells that constitutively express N2ICD as a result of the GFAP-CreER
T2-mediated excision event. YFPþ cells in GCE/YFP mice were used as
controls. YFPþ cells expressing a proliferation marker (Ki67) or differentiation markers (Sox2, GFAP, Dcx, NeuN) were used for quantiﬁcation in (b)o r( c), respectively.
(b) Quantiﬁcation of YFP/Ki67þ cells revealed a twofold increase in proliferating YFPþ cells in GCE/YFP/N2ICD mice compared with GCE/YFP mice in both the SGZ and
SVZ, indicating increased proliferation in the neurogenic niche of adult mice with N2ICD expression. (c) Immunostaining for YFP and NSC markers (Sox2, GFAP; left panels)
or neuronal markers (Dcx, NeuN; right panels) in the dentate gyrus in GCE/YFP/N2ICD and GCE/YFP mice. Quantiﬁcation reveals that GCE/YFP/N2ICD mice have
approximatelyatwofoldincreaseinYFPþ cellsexpressingNSCmarkerscomparedwithGCE/YFPmice,whilethenumberofYFPþ neuronsisstronglydecreased(d).This
indicates that N2ICD expression increases the number of NSCs, while preventing neurogenesis. GCL¼granule cell layer. Bar diagrams show mean±S.E.M., *Po0.05,
***Po0.01 (Student’s t-test). Scale bars are (c)¼25mm
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Cell Death and Diseaseshowed a negative correlation (rs¼ 0.56 and  0.52). This
further implicates Notch2 into GBM survival. NSC/GSC
markers (Sox2 and Nestin) positively correlated with Notch2
expression (rs¼0.62 and 0.49), supporting that Notch2
levels correlate with an increase in GSC cells. The
expression of the astrocyte markers Vimentin and GFAP
highly correlated with Notch2 expression (rs¼0.75 and
0.76), in line with Notch2 directing astrocyte versus
oligodendrocyte fate decisions. In contrast, transcripts for
oligodendrocyte markers (CNP, PLP1 and Olig2) showed a
strong negative correlation with Notch2 transcript levels
(rs¼ 0.88,  073 and  0.56). In summary, this correla-
tion analysis further supports that Notch2 signaling con-
tributes to the cellular identity of GBM.
Discussion
Developmentally stalled NSCs are a possible source of GSCs
giving raise to malignant glioma.
2–7 NSCs inherently have the
features of tumor cells (e.g., multipotency, self-renewal
capacity, high motility and robust proliferative potential) and
thereforeare at risk formalignant transformation.
2–7 Notch2is
highly expressed in GBM
8 and N2ICD expression in GBM cell
xenografts signiﬁcantly reduced survival.
9 In contrast, loss of
Notch2 is frequently found in oligodendroglioma and low
Notch2 levels correlate with a much better prognosis.
10 Here,
we used a transgenic approach to study whether constitutive
Notch2 signaling in NSCs has a role in proliferation,
differentiation and apoptosis, and possibly contributes to
GBM formation. In support of this, we found that Notch2
signaling in NSCs in vivo increases cell proliferation and
prevents neuronal differentiation,both inembryos andin adult
mice.Importantly,N2ICDexpressionisnotsufﬁcienttoinduce
tumors but leads to a prominent expansion of the neurogenic
niche. Furthermore, N2ICD expression in cultured NSCs
promotes astrocyte differentiation at the expense of neuronal
and oligodendrocyte differentiation. The expression of N2ICD
in NSCs also increased the resistance to apoptosis, rendering
these NSC less sensitive to the cytotoxic drug etoposide. Our
ﬁndingsthereforeindicatethatconstitutiveNotch2signalingin
NSCs is sufﬁcient to induce key features of GSCs. In addition,
they suggest that constitutive Notch2 signaling could promote
NSCs to give rise to tumors of the astrocytic rather than the
oligodendroglial lineage.
We addressed whether Notch2 signaling is responsible for
some of the features of GBM expressing high Notch2 levels.
We found that blocking endogenous Notch signaling in
cultured GBM cells reduces proliferation, whereas N2ICD
Figure 4 Notch2 signaling regulatesNSC proliferation and differentiation in vitro.( a) Nestin-Cre/N2ICD neurospheres overexpressing N2ICD have increasedsphere size
compared with single transgenic N2ICD control spheres. (b) Quantiﬁcation of neurosphere diameters showed that the median diameter in Nestin-Cre/N2ICD spheres was
increased by 75% when compared with control spheres, suggesting that N2ICD expression increases NSC proliferation. (c) Immunostainings of differentiated Nestin-Cre/
N2ICD and control NSCs for neuronal (Tuj1, arrows), astrocytic (GFAP) and oligodendrocytic (Olig2, arrowheads) markers. Quantiﬁcation of cells expressing marker proteins
in percent of DAPIþ nuclei reveals that N2ICD largely blocks neuronal differentiation (d) and increases the number of astrocytes (e). Furthermore, Nestin-Cre/N2ICD NSCs
almost completely lost their ability to differentiate into Olig2þ oligodendrocytes (f). (g) GFAP protein levels were highly increased in western blot analysis of differentiated
Nestin-Cre/N2ICD NSCs, whereas Tuj1 levels diminished. (h) NSCs overexpressing N2ICD were more resistant to apoptosis. Lower levels of cleaved Caspase-3 were
detectedintheN2ICD-expressingNSCsafteretoposidetreatment.Boxplotdiagramsshowmedian(redline),boxed25and75%percentiles,whilewhiskersmarkminimaand
maxima(Mann–Whitneytest,Po0.0001).Bardiagramsshowmean±S.E.M.,*Po0.05,**Po0.01(Student’st-test).Nestin-CremediatesﬂoxedStopcodonexcisioninthe
entire neural lineage.
22 All quantiﬁcations are therefore based on the total number of cells. Scale bar (b and c)¼100mm
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Cell Death and Diseaseexpression signiﬁcantly increases proliferation. Furthermore,
we observed that N2ICD expression in cultured GBM cells
causes an upregulation of anti-apoptotic proteins and
increases cell survival. These results are in line with N2ICD
expression increasing proliferation and reducing apoptosis in
HSR–GBM1 cells and xenografts thereof.
9 Enhanced pro-
liferation and survival of GBM cells with elevated Notch2
levels may therefore provide an explanation for the poor
prognosis of GBM with high Notch2 levels and the better
prognosis of oligodendroglioma with Notch2 deletions.
9,10
We found that Notch2 expression levels in GBM biopsies
positively correlate with the transcript levels of genes
controlling stemness (Sox2, Nestin) and astrocyte fate
(Vimentin, GFAP), while they negatively correlate with the
Figure 5 Notch2 signaling controls proliferation in GSC-like cells. (a) Compared to spheres derived from the parental U373 cell line (WT), spheres overexpressing N2ICD
are increasedin size (N2ICD), indicating increasedproliferation of GSC-like cells. In contrast, spheres derivedfrom U373 cells expressing MAML1dn, whichinhibitscanonical
Notch signaling, were smaller in size (MAML1dn). (b) Quantiﬁcation shows that U373-N2ICD spheres have twice the diameter compared with U373-WT spheres, whereas
U373-MAML1dn spheres show a decrease in diameter by 25%. (c) Immunostaining of U373-N2ICD spheres for GSC markers (Nestin, Sox2 and CD133) conﬁrms that the
spheres retain stem-like properties. Box plot diagrams show median (red line), boxed 25 and 75% percentiles, while whiskers mark minima and maxima (Mann–Whitney test,
Po0.0001). Scale bar (a)¼100mm, (c)¼50mm
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Cell Death and Diseasetranscript levels of genes controlling oligodendrocyte fate
(Olig2, CNP, PLP1). In addition, Notch2 expression levels in
GBM biopsies positively and negatively correlate with the
expression levels of antiapoptotic (BCL6, BCL2L12) and
proapoptotic (Bax, BCLAF1) markers, respectively.
The enhanced proliferation seen in the presence of Notch2
signaling may stochastically increase the risk of NSCs to
acquire somatic mutations and to transit to GSCs. If the
increasedNotch2signaling occursafter GSCsareformed this
would likely promote GSCs to give rise to astrocytomas, such
as GBM, rather than oligodendroglioma. A loss of Notch2
signaling in subsets of expanding GSCs with Notch2
ampliﬁcation could explain the formation of mixed oligoden-
droglioma. In any instance, blockade of Notch2 signaling may
interfere with GBM formation and thus be of therapeutic
beneﬁt. Unfortunately, pan-Notch inhibitors (e.g., g-secretase
inhibitors)producesevereside-effectsintheintestinalcrypt.
31
As genetic deletion of either Notch1 or Notch2 receptors does
not result in intestinal phenotypes, a speciﬁc therapeutic
targeting of Notch2 receptors may still be possible.
32
Genentech developed therapeutic antibodies speciﬁcally
targeting the Adam protease cleavage-site in the Notch1 or
Notch2 receptors.
33 Although the antibody blocking Notch1
signaling efﬁciently inhibits proliferation of T-cell acute
lymphoblastic leukemia cells, no data are available yet for
the antibody blocking Notch2 signaling.
33 It certainly would be
interesting to test such an antibody for the treatment of GBM.
On a different note, the developmental phenotypes seen in
mice expressing N2ICD in NSCs shed light on the functions of
Notch2 signaling during embryonic and adult neurogenesis.
The pronounced hyperplasia of the neurogenic niche during
embryonic development and the ensuing lack of a properly
developed striatum indicate that Notch2 not only expands the
NSC pool but that Notch2 downregulation is also important
to allow subsequent NSC differentiation. Reduced neuronal
differentiation of adult NSCs expressing N2ICD within the
SGZofthedentategyrussupportsthatNoch2downregulation
is also important for adult neurogenesis. These ﬁndings are in
line with Notch2 inhibiting differentiation of cerebellar granule
neuron precursors
14 and keeping astrocytes in an immature
state.
34 Our developmental studies show that Notch2 has a
role in regulating differentiation and proliferation of NSCs in
the embryonic and adult brain.
In conclusion, Notch2 signaling in NSCs induces key
features of GSCs, such as increased proliferation, reduced
apoptosis and induces astrocytic lineage entry. In addition,
high/constitutive Notch2 expression may favor the formation
of astrocytoma, in particular GBM. Of note, however, high/
constitutive Notch2 expression is not sufﬁcient to induce GBM
formation, which probably requires the acquisition of addi-
tional mutations.
Materials and Methods
Mice. N2ICD mice
23 were crossed with heterozygous Nestin-Cre mice
22 to
obtain double transgenic Nestin-Cre/N2ICD mice that allow N2ICD expression in
the neural lineage
22,35 (Figures 1a, b). Single transgenic N2ICD mice were used
as littermate controls. N2ICD mice were crossed with GFAPCre-ER
T2 (hereafter
GCE) mice
24 containing a Cre/LoxP inducible Rosa26-YFP reporter gene
(hereafter YFP)
25 resulted in triple transgenic GCE/YFP/N2ICD mice expressing
N2ICD in the adult NSC niche and in astrocytes (Figures 3a, c and data not shown).
GCE/YFP mice were used as littermate controls. Intraperitoneal administration of
tamoxifen (2mg, Sigma, St. Louis, MO, USA) once daily for 5 consecutive days
was used for Cre-mediated excision of ﬂoxed STOP cassettes in 8–10-week-old
GCE/YFP/N2ICD mice and GCE/YFP mice. Mice were killed 7 days after the last
tamoxifen injection and perfused with paraformaldehyde. Genotyping was
performed with TaqMan-PCR primers (YFP mice: sense 50-ACAGCTCGTCCAT
GCCGA-30, antisense 50-ATCACATGGTCCTGCTGGAGT-30, probe 50-FAM-TGA
TCCCGGCGGCGGTCA-TAMRA-30; N2ICD mice: sense 50-ATATCCGCGGTGGA
GATCAA-30, antisense 50-TAGACCAGGCTGGGCTAAA-30, probe 50-VIC-CGGTA
CCAGATCTC-MGB-30; Nestin-Cre/GCE mice: sense 50-GCCGCGCGAGATATGG-30,
primer antisense 50-GCCACCAGCTTGCATGATC-30, probe 50-FAM-CCGCGCT
Figure 6 N2ICD expression increases resistance of U373 GBM cells to
apoptosis. (a) U373-N2ICD GBM cells expressing N2ICD are more resistant to
etoposide-induced apoptosis. Less Caspase-3 protein is cleaved in U373-N2ICD
GBM cells compared with U373-GFP GBM cells (left panel). U373-N2ICD GBM
cells with increased N2ICD protein levels have increased Mcl1 and Bcl2 protein
levels when compared with U373-GFP cells, indicating that Notch2 signaling
increases the resistance to apoptosis by upregulation of anti-apoptotic factors.
Actins controls for sample loading (right panel). (b) Similar levels of Caspase-3
cleavage are observed in U373-MAML1dn and U373-GFP GBM cells, supporting
that the inhibition of canonical Notch signaling does not increase apoptosis in
response to etoposide treatment (left panel). Likewise, Bcl2 and Mcl1 protein levels
are similar in U373-MAML1dn compared with U373-GFP GBM cells. Actin protein
levels control for sample loading (right panel)
Figure 7 Notch2 mRNA levels in primary human GBM correlate with mRNA
levels of genes inhibiting apoptosis, promoting stemness and inducing astrocyte
differentiation. Correlation coefﬁcients for Notch2 and genes involved in apoptosis
(blue) and differentiation (red/purple) as well as Notch2 targets (green) are shown
as Spearman’s Correlations with a P-value of less than 0.05. The correlation
coefﬁcient (0.98) for another Notch2 probe is included as a positive control
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in accordance with institutional guidelines approved by the veterinary ofﬁce of
Basel-Stadt.
Immunohistochemistry and immunoblots. Immunostaining and
immunoblots were performed as described
23 with rabbit anti-Caspase-3 (#9062,
Cell Signaling, Beverly, MA, USA), mouse anti-beta-Actin (A5316, Sigma), anti-
Bcl-2 (Santa Cruz, Santa Cruz, CA, USA) and anti-Mcl1 (Santa Cruz), mouse anti-
NeuN (Chemicon, Billerica, MA, USA), rabbit anti-GFAP (Dako, Glostrup,
Denmark), mouse anti-GFAP (Chemicon), rat anti-Notch2 (Developmental Studies
Hybridoma Bank, Iowa City, IA, USA), mouse anti-Myc (SC-40, Santa Cruz), goat
anti-Myc (Santa Cruz), rat anti-Substance-P (Abcam, Cambridge, UK), rabbit anti-
Ki67 (Novocastra, Newcastle, UK), rabbit anti-Gad65/67 (Sigma), rabbit anti-Olig2
(Chemicon) goat anti-Sox2 (R&D Systems, Abingdon, UK), goat anti-Dcx (Santa
Cruz), chicken anti-GFP (Molecular Probes/Invitrogen, Carlsbad, CA, USA),
mouse anti-Nestin (Santa Cruz), rabbit anti-CD133 (Santa Cruz), mouse anti-bIII-
Tubulin (Tuj1) (Sigma), mouse anti-Myc (Santa Cruz) and rabbit anti-Caspase-3
(Cell Signaling) antibodies. The secondary antibodies used were Alexa-conjugated
or horseradish peroxidase-conjugated (Jackson Immunoresearch, Newmarket,
UK). Image analysis was performed with a Leica DMI6000 ﬂuorescence
microscope or a Zeiss LSM510 confocal microscope and ImageJ software (NIH,
Bethesda, MD, USA).
Neurospheres. NSC cultures were prepared and maintained as described.
36
For determination of neurosphere number and size, 100ml samples containing
comparable numbers of cells from each genotype were transferred into wells of a
96-well plate and grown for 5 days. For in vitro differentiation, cells were seeded at
a density of 2 10
5cells/cm
2 on coverslips coated with 15mg/ml poly-L-ornithin
and 40mg/ml laminin. Cells were differentiated in neurosphere medium lacking
FGF2, EGF and heparin, and ﬁxed after 5 days with 4% PFA.
Stable expression of N2ICD in GBM cell lines. U373 GBM cells
37
were grown and stably transfected as described.
8 N2ICD (nucleotides 5107–7425
of the human Notch2 cDNA, AF308601) was expressed from pcDNA3.0-IRES-
EGFP, dominant-negative Mastermind-like I (MAML1dn) from pEGFP-N3-
MAML1dn (gift of Dr. Aster, HMS, Boston, MA, USA)
27 and GFP from
pcDNA3.1-IRES-EGFP as control. For culturing GSC-like spheres from GBM,
U373 GBM cells were cultured under the same conditions as neurospheres.
Parental U373 cells (WT) were used as controls.
RT-PCR quantiﬁcation. Total RNA was isolated from whole brain of E16.5
embryos using the SV-total-RNA isolation system (Promega, Wallisellen,
Switzerland) and used as template to synthesize cDNA with GoScript reverse
transcriptase (Promega). Relative quantitative RT-PCR was performed using the
Power-SYBR-Green PCR Master Mix (Applied Biosystems, Zug, Switzerland)
according to manufacturer’s protocol. Data were normalized to GAPDH cDNA. The
following primers were used for Notch2 (sense 50-CCCAAGGACTGCGAGTCA
GG-30, antisense 50-GGCAGCGGCAGGAATAGTGA-30), Hes1 (sense 50-CTACC
CCAGCCAGTGTCAAC-30, antisense 50-AAGCGGGTCACCTCGTTCAT-30), Hey1
(sense 50-CTTGAGTTCGGCGCTGTGTTCC-30, antisense 50-GATGCCTCTCCGT
CTTTTCCT-30) and GAPDH (sense 50-TTAGCCCCCCTGGCCAAGG-30, anti-
sense 50-CTTACTCCTTGGAGGCCATG-30).
Pharmacological induction of apoptosis. After growing 6 days in vitro
(div) neurospheres (2–4 passages, Nestin-Cre/N2ICD and single transgenic
N2ICD controls) were dissociated to obtain a single cell suspension. Cells were
plated at a density of 5 10
4cells/ml in a 6-well plate (BD, Franklin Lakes, NJ,
USA) in neurosphere medium for 4 days to allow neurosphere formation. On the
4th day etoposide (Sigma) was added at a concentration of 20mM for either 6
or 10h. Untreated neurospheres were used as a control. Neurospheres were
harvested by centrifugation at 300 g for 5min and lysed. U373 GBM cells stably
transfected either with N2ICD, MAML1dn or GFP were plated at 5 10
4cells/ml.
After 2 days 20 or 40mM etoposide was added for 24h and protein extracts were
obtained as described above. Apoptosis induction was assessed by immunoblot
detection of cleaved Caspase-3 from at least three independent experiments.
Correlation Analysis. For bioinformatics analysis, we used absolute
expression values from recently published microarray data.
30 Brieﬂy, labeled total
RNA from two normal brains and 15 GBM samples was hybridized to Affymetrix
U133v2.0 Gene. Data-mining was performed using the Genedata Analyst 4.1
package (Genedata, Basel, Switzerland). All samples were quantile normalized
and median scaled to correct for minor variation in expression distribution.
Expression values for speciﬁc genes were used to calculate Spearman’s
correlation coefﬁcients.
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